Radioactive 'Warhead' targets tough hodgkin lymphoma in new transplant strategy
NCT ID NCT04871607
Summary
This study is testing a new two-part treatment for Hodgkin lymphoma that has not responded to or has returned after initial therapy. First, a radioactive antibody is given to seek out and kill cancer cells. Then, high-dose chemotherapy and a patient's own stem cells are used to try to control the disease long-term. The main goal is to see if this approach helps patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.